NCT05525130 (FAGOTRICIA) is a NA clinical trial of Food supplement in Lithiasis, sponsored by Arafarma Group, S.A..

Who is sponsoring NCT05525130?

NCT05525130 is sponsored by Arafarma Group, S.A..

What drugs are being tested in NCT05525130?

Interventions in NCT05525130: Food supplement, Placebo.

What condition does NCT05525130 study?

NCT05525130 studies Lithiasis, Nephrolithiasis.

Is NCT05525130 still recruiting?

NCT05525130 is currently completed. Last updated 23 February 2023.

Last reviewed 2023-02-23 · How we verify

NCT05525130: FAGOTRICIA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of the Administration of a Food Supplement in Patients With Lithiasis Treated With Extracorporeal Shock Wave Lithotripsy.

Completed NA Last updated 23 February 2023

What this trial tests

NA trial testing Food supplement in Lithiasis in 81 participants. Completed in 5 October 2022.

Timeline

22 April 2020

Primary endpoint
16 September 2022

5 October 2022

Quick facts

Lead sponsor	Arafarma Group, S.A.
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	81
Start date	22 April 2020
Primary completion	16 September 2022
Estimated completion	5 October 2022
Sites	3 locations across Spain

Drugs / interventions tested

Food supplement
Placebo

Conditions studied

Lithiasis — all drugs for Lithiasis →
Nephrolithiasis — all drugs for Nephrolithiasis →

Sponsor

Arafarma Group, S.A. — full company profile →

Who can join

18 and older, any sex, with Lithiasis or Nephrolithiasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The extracorporeal shock wave lithotripsy (ESWL) is the treatment of choice for most stones in any of their locations. It is about breaking the stone without surgically intervening on the patient and getting him to expel the fragments himself. It is thought that additional treatments to the ESWL could improve the success rate of ESWL for less favorable stones. The components of our authorized food supplement have shown an inhibitory effect in vitro on the growth of calcium oxalate monohydrate crystals, even in hightly supersaturared solutions. Also these components show an inhibitory effect on the growth of calcium phosphate crystals. To sum up, it reduces the formation, inhibits the growth and promotes the dissolution of calcium oxalate and calcium phosphate kidney stones. This is the reason why this experimental study aims to modify the size limit of the stones in the ESWL with adjuvant food supplement.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

A randomized, double-blind, placebo-controlled clinical trial of the use of hydroxycitric acid adjuvant to shock wave lithotripsy therapy in patients with calcium stones. Stone fragmentation results.
Del Carmen Cano García M, Cobos RC, Bohorquez ÁV, Díaz PM, et al · · 2023 · cited 1× · PMID 37249658 · DOI 10.1007/s00240-023-01456-0

Verify or expand the search:

Other trials of Food supplement

Trials testing the same drug.

NCT06751810 — Nutritional Status in Children With Food Allergy: Evaluation of a New Supplement · NA · completed
NCT06727292 — Biometrical Evaluation of the Efficacy of a Food Supplement Versus Placebo · NA · recruiting
NCT07199556 — Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors. · NA · completed
NCT05718908 — Study of the Symptomatic Improvement in Patients With Fibromyalgia by Means of a Food Supplement · completed
NCT04815499 — Effects of a Food Supplement on Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. · NA · completed

Other Arafarma Group, S.A. trials

Trials by the same sponsor.

NCT07393958 — Impact of Food Supplementation on Quality of Life in Patients With Endometriosis and Pelvic Pain. · NA · recruiting
NCT07199556 — Impact of a Food Supplement on Musculoskeletal Pain in Women With Breast Cancer Treated With Aromatase Inhibitors. · NA · completed
NCT05718908 — Study of the Symptomatic Improvement in Patients With Fibromyalgia by Means of a Food Supplement · completed
NCT04815499 — Effects of a Food Supplement on Quality of Life in Patients With Chronic Obstructive Pulmonary Disease. · NA · completed
NCT05109455 — Effects of a Food Supplement in the Prevention of Urinary Tract Infections in Kidney Transplant Patients. · Phase 4 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05525130 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Arafarma Group, S.A.
Last refreshed: 23 February 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05525130.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing